Source:http://linkedlifedata.com/resource/pubmed/id/21138749
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2011-4-25
|
pubmed:abstractText |
Taking advantage from the development of SV30, a new analogue of the pro-apoptotic molecule HA14-1, the aim of this study was to functionally evaluate SV30 and to develop safe nanocarriers for its administration. By using an inversion phase process, 57nm organic solvent-free lipid nanocapsules loaded with SV30 (SV30-LNCs) were formulated. Biological performance of SV30 and SV30-LNCs were evaluated on F98 cells that express Bax and Bcl-2, through survival assays, HPLC, flow cytometry, confocal microscopy and spectral imaging. We observed that SV30 alone or in combination with paclitaxel, etoposide or beam radiation could trigger cell death in a similar fashion to HA14-1. Although partially blocked by Z-VAD-fmk, this effect was coincident to caspase-3 activation. Hence, we established that SV30-LNCs improved SV30 biological activity together with a potentiation of the mitochondrial membrane potential decrease. Interestingly, flow cytometry and confocal analysis indicated that SV30 itself conferred to LNCs improved mitochondrial targeting skills that may present a great interest toward the development of mitochondria targeted nanomedicines.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzopyrans,
http://linkedlifedata.com/resource/pubmed/chemical/Caspase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Nanocapsules,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/ethyl...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1873-4995
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright © 2010 Elsevier B.V. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
10
|
pubmed:volume |
151
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
74-82
|
pubmed:dateRevised |
2011-11-2
|
pubmed:meshHeading |
pubmed-meshheading:21138749-Animals,
pubmed-meshheading:21138749-Antineoplastic Agents,
pubmed-meshheading:21138749-Benzopyrans,
pubmed-meshheading:21138749-Caspase 3,
pubmed-meshheading:21138749-Cell Line, Tumor,
pubmed-meshheading:21138749-Glioma,
pubmed-meshheading:21138749-Lipids,
pubmed-meshheading:21138749-Mitochondria,
pubmed-meshheading:21138749-Nanocapsules,
pubmed-meshheading:21138749-Nitriles,
pubmed-meshheading:21138749-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:21138749-Rats
|
pubmed:year |
2011
|
pubmed:articleTitle |
Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1.
|
pubmed:affiliation |
Inserm, UMR-S 646, Angers, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|